temozolomide has been researched along with creatine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Abud, L; Capelle, L; Chiras, J; Costalat, R; De Marco, G; Guillevin, R; Habas, C; Hoang-Xuan, K; Menuel, C; Taillibert, S; Vallée, JN | 1 |
| Barboriak, DP; Bokstein, F; Boxerman, JL; Gilbert, MR; McKinstry, RC; Ratai, EM; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Brem, S; Chawla, S; Mohan, S; Peters, KB; Poptani, H; Skolnik, A; Verma, G; Wang, S | 1 |
| Butowski, N; Cha, S; Chang, SM; Clarke, J; Crane, JC; Li, Y; Lupo, JM; Molinaro, A; Nelson, SJ; Olson, M; Prados, M; Roy, R | 1 |
| Butowski, N; Cha, S; Chang, S; Crane, J; Kadambi, AK; Li, Y; Molinaro, A; Nelson, SJ; Olson, M; Park, I; Roy, R | 1 |
1 trial(s) available for temozolomide and creatine
| Article | Year |
|---|---|
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Choline; Creatine; Dacarbazine; Feasibility Studies; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prognosis; Prospective Studies; Survival Rate; Temozolomide | 2013 |
5 other study(ies) available for temozolomide and creatine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Brain Neoplasms; Choline; Creatine; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Prospective Studies; Protons; Temozolomide; Treatment Outcome | 2011 |
Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience.
Topics: Anisotropy; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Blood Volume; Choline; Creatine; Dacarbazine; Electric Stimulation Therapy; Electromagnetic Fields; Female; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Middle Aged; Outcome Assessment, Health Care; Temozolomide; Thalamus | 2016 |
Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Aspartic Acid; Bevacizumab; Brain Neoplasms; Choline; Creatine; Dacarbazine; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Proton Therapy; Statistics, Nonparametric; Temozolomide; Young Adult | 2016 |
Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choline; Cohort Studies; Combined Modality Therapy; Creatine; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Grading; Prognosis; Radiotherapy, Conformal; Survival Rate; Temozolomide; Tumor Burden | 2017 |